Myeloid-derived suppressor cells (MDSCs) play critical roles in primary and metastatic cancer progression. MDSC regulation is widely variable even among patients harbouring the same type of malignancy, and the mechanisms governing such heterogeneity are largely unknown. Here, integrating human tumour genomics and syngeneic mammary tumour models, we demonstrate that mTOR signalling in cancer cells dictates a mammary tumour's ability to stimulate MDSC accumulation through regulating G-CSF. Inhibiting this pathway or its activators (for example, FGFR) impairs tumour progression, which is partially rescued by restoring MDSCs or G-CSF. Tumour-initiating cells (TICs) exhibit elevated G-CSF. MDSCs reciprocally increase TIC frequency through activating Notch in tumour cells, forming a feedforward loop. Analyses of primary breast cancers and patient-derived xenografts corroborate these mechanisms in patients. These findings establish a non-canonical oncogenic role of mTOR signalling in recruiting pro-tumorigenic MDSCs and show how defined cancer subsets may evolve to promote and depend on a distinct immune microenvironment.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population defined as CD11b + Gr1 + cells. They can be roughly divided into granulocytic and monocytic subsets using Ly6G and Ly6C as markers, respectively. Both CD11b + Ly6G + and CD11b + Ly6C + cells have immunosuppressive activities, although different mechanisms may be used. The granulocytic subset is more often found expanded in tumour models and is involved in promoting tumour progression [1] [2] [3] [4] , although anti-tumour effects have also been observed 5 . In the clinic, MDSCs were first identified in the peripheral blood of cancer patients as non-lymphoid haematopoietic suppressor cells 6 that have been subsequently shown to increase during progression in many cancer types 7, 8 . Similar to mouse, most human MDSCs carry markers of immature myeloid lineage cells and qualify as either granulocytic (CD11b + CD33 + CD15 + HDLA low ) or monocytic (CD11b + CD14 + HDLA low ) subsets 3,4,9 . Considerable information has been obtained about the biogenesis and functions of MDSCs. The cytokines responsible for MDSC accumulation include G-CSF [10] [11] [12] [13] [14] , GM-CSF 15 , IL-1β 16, 17 , IL-6 18 , PGE2 19 , IFN-γ 20 , IL-4 21 and VEGF 22 . The immunosuppressive mechanisms used by MDSCs involve secretion of TGFβ, generation of nitric oxide and reactive oxygen species, and metabolic depletion of L-arginine by arginase 1 (refs 1,2) . These activities can blunt cytotoxicity, block proliferation or induce apoptosis of cytotoxic T lymphocytes and natural killer cells. Other MDSC functions include formation of a pre-metastatic niche 23 , enhancement of tumour invasion 24, 25 and stimulation of angiogenesis 25 .
Despite this knowledge, we have a limited understanding of why and how individual tumours vary widely in their propensity to induce MDSCs. Here, we demonstrate that this propensity is determined by an oncogenic signalling pathway and linked to the subpopulation of tumour-initiating cells (TICs).
RESULTS

Inter-tumoral heterogeneity of MDSC infiltration
We examined myeloid cells in a variety of syngeneic mammary tumour models of diverse genetic backgrounds and tumorigenic drivers. MMTV-WNT1, MMTV-WNT1-iFGFR and P53-PTEN double knockout (DKO) are genetically engineered mouse models in the FVB background. MMTV-WNT1 is a widely used model of basallike tumours. WNT1-iFGFR is a bigenic model based on MMTV-WNT1, in which FGFR signalling can be inducibly activated 26, 27 . The P53-PTEN DKO was generated by conditional deletion of these tumour suppressors using a MMTV-driven Cre. P53N tumour lines initially arose from transplanted P53-null mammary gland tissues in BALB/c mice, and are maintained through mouse-tomouse orthotopic transplantation. Despite the common loss of P53, P53N lines exhibited remarkable inter-tumoral heterogeneity in genomic copy number, gene expression profiles and TIC frequencies 28 . The 67NR-4TO7-4T1 series are established cell lines derived from a spontaneous tumour in BALB/c mice. Taken together, these reagents provide an unbiased representation of available syngeneic models.
Mammary tumours were generated either by spontaneous tumorigenesis (MMTV-WNT1, WNT1-iFGFR and P53-PTEN DKO), or orthotopic transplantation of primary tumour tissues (P53N series) or cell suspensions (67NR, 4TO7, and 4T1). When tumours reached 1 cm 3 , we examined myeloid cell infiltration by immunofluorescence staining of S100A8, which was predominantly expressed by CD11b + Gr1 + cells rather than tumour cells ( Supplementary Fig. 1b ). Significant inter-tumoral heterogeneity was discovered ( Fig. 1a and Supplementary Fig. 1a ). Quantification of CD11b + Gr1 + cells in dissociated tumours was largely consistent with S100A8 staining (Fig. 1b ). The accumulation of CD11b + Gr1 + cells is systemic, as they were also found in peripheral blood and the frequencies closely correlated with the tumour-infiltrating myeloid cells ( Fig. 1c,d) . Overall, the inter-model variations of CD11b + Gr1 + cells were as high as 50-to 100-fold. In contrast, tumours of the same model exhibited only a 2-to 5-fold variation (Fig. 1b) . Thus, the local and systemic accumulation of CD11b + Gr1 + cells seems to be a stable trait of each tumour line.
Most CD11b + Gr1 + cells expressed a high level of Ly6G and a variable level of Ly6C (Fig. 1e ), and exhibited a granulocytic morphology ( Fig. 1f ). Neutrophils isolated from tumour-free mice also express CD11b and Ly6G. However, P53N-C tumour-induced CD11b + Ly6G + cells differ from normal neutrophils by their heterogeneous expression of Ly6C (Fig. 1e ), which typically indicates an immature status 29 . Co-culture of CD11b + Gr1 + cells with T cells inhibited CD3-and IL-2-induced T-cell proliferation and IFN-γ production (Fig. 1g,h and Supplementary Fig. 1c ), whereas normal neutrophils did not exhibit these effects ( Fig. 1h and Supplementary  Fig. 1c ). Moreover, iNOS expression is over 500-fold higher in CD11b + Ly6G + cells than in normal neutrophils (Fig. 1i ). Thus, these CD11b + Gr1 + cells are immunosuppressive and, therefore, MDSCs by definition.
MDSCs can be depleted by administration of a monoclonal antibody against Gr1 (ref. 12) . The depletion inhibited orthotopic growth of P53N-C tumours (Fig. 1j ). Moreover, treatment following orthotopic tumour resection significantly reduced distant metastasis to lungs (Fig. 1k ) demonstrating the tumour-promoting role of MDSCs.
The oncogenic mTOR pathway dictates MDSC accumulation
To identify the determinant of inter-tumoral heterogeneity of MDSCs, we performed reverse-phase protein array (RPPA) analysis of 200 (phos-)proteins covering major signalling pathways (Supplementary Table 1 ). MDSC accumulation correlated with the AKT-mTOR and the MAPK pathways across the WNT1, WNT1-iFGFR and P53-PTEN DKO models, and only the AKT-mTOR pathway in the P53N series ( Fig. 2a ), suggesting that the mTOR pathway is a likely driver of MDSC accumulation. This was largely confirmed by western blot analysis in P53N tumours ( Fig. 2b) as well as in the 67NR-4TO7-4T1 series (Fig. 2c ).
Treatment with rapamycin, an mTOR inhibitor, reduced MDSCs in P53N-C-tumour-bearing mice (Fig. 2d ). Rapamycin may affect non-cancer cells including MDSCs themselves. To verify that the mTOR activity responsible for MDSC accumulation is cancer cellintrinsic, we employed a short hairpin RNA (shRNA) to deplete Raptor, an essential protein of the mTOR complex 1, in 4T1 cancer cells ( Supplementary Fig. 2 ). This depletion resulted in a significant reduction of MDSCs in vivo ( Fig. 2e ). We also observed an increase of overall T cells and a decrease of PD1 + T cells (Fig. 2f ). These data strongly support that the oncogenic mTOR signalling may mediate this systemic immunosuppression.
To further distinguish cancer cell-autonomous functions of mTOR from its systemic impact through MDSCs, we performed a 'rescue' experiment by adoptively transferring MDSCs into rapamycin-treated animals bearing P53N-C tumours ( Fig. 2g ), or into animals transplanted with 4T1 cells expressing the shRNA against Raptor (Fig. 2h ). In both cases, tumour progression was partially restored (Fig. 2g,h) . In contrast, normal neutrophils were unable to rescue tumour progression ( Fig. 2h ). Thus, at least part of the tumour-promoting effects of the mTOR pathway is through MDSC induction.
The mTOR pathway drives expression of G-CSF
We surveyed over 20 cytokines using multiplexed luminex assays in some P53N models. The serum G-CSF concentration was higher in the P53N-C model than in tumour-free or P53N-A. Other cytokines did not exhibit this trend ( Fig. 3a ). Expression of a constitutively active mTOR mutant 30 in P53N-A tumours led to increased expression of G-CSF (Fig. 3b ). Conversely, rapamycin treatment on P53N-C cells/tumours resulted in the reduction of G-CSF in conditioned medium or in serum ( Fig. 3c,d ). For 4T1 cells, either rapamycin treatment or genetic depletion of Raptor also decreased G-CSF expression ( Fig. 3e,f ). Taken together, these data support that G-CSF is a downstream target of the mTOR pathway in tumour cells.
We asked whether systemic restoration of G-CSF could rescue delayed tumour progression caused by mTOR inhibition. Figure 1 Inter-tumoral heterogeneity of MDSC infiltration. (a) Representative immunofluorescence staining of S100A8 in the indicated tumours. Green, S100A8; blue, DAPI (nucleus Supplementary Table 4 . Percentage of In b,c,e,f, two independent experiments were conducted each with technical triplicates. One representative experiment is shown. (g) Growth curves of 4T1 cells expressing Raptor shRNA (n = 12 animals) or scrambled shRNA (n = 6 animals). On day 17 after tumour transplantation, the Raptor shRNA group was randomized into two groups (n = 6 animals each), one of which received G-CSF. The P values were determined using general linear models accounting for repeated measurements at different time points. (h) Representative H&E staining and pulmonary metastasis quantification from the experiments in g, day 28 post tumour transplantation. n = 5 animals for the first two groups, and n = 4 for the third group. Ten fields were randomly chosen from each animal and averaged. P values are calculated by one-tailed Student's t tests. Scale bars, 200 µm and 50 µm in the upper and lower panels, respectively. (i,j) Tumour volume (i) and lung metastasis (j) of 4T1 cells expressing G-CSF shRNA or vector control (n = 8 animals). On day 17, the G-CSF shRNA group was randomized into three groups: untreated (G-CSF shRNA, n = 7 animals), treated with MDSCs (G-CSF shRNA + MDSCs, n = 7 animals) or treated with Gr1 + splenocytes of tumour-free mice (G-CSF shRNA + Gr1 + , n = 4 animals). Tumour volumes on day 24 and lung metastases on day 35 are shown. The lung metastasis burden was graded as described in Methods. P values are calculated by two-tailed Student's t tests. Scale bar, 5 mm. Error bars indicate s.e.m. Statistics source data for c,i,j, provided in Supplementary Table 4 .
We administered recombinant G-CSF protein to mice bearing 4T1 tumours expressing the shRNA against Raptor. This treatment restored orthotopic tumour growth and pulmonary metastasis ( Fig. 3g,h) . Thus, G-CSF functionally mediates at least part of the tumour-promoting functions of mTOR. The role of G-CSF in MDSC formation and tumour progression has been investigated in previous studies [10] [11] [12] [13] [14] 31 . To confirm these effects in our models, we depleted G-CSF either by a neutralizing antibody in the P53N-C model or by shRNA-mediated knockdown in the 4T1 model. These approaches lowered serum G-CSF by 50% or 70%, respectively ( Supplementary Fig. 3a,b ), resulted in a decrease of MDSCs ( Supplementary Fig. 3c,d) , and retarded tumour progression and metastasis ( Fig. 3i,j) . Importantly, this retardation was reversed by adoptive transfer of MDSCs but not splenic Gr1 + cells from tumour-free mice ( Fig. 3i,j) . The depletion of G-CSF did not generate discernible effects on cancer cells in vitro ( Supplementary  Fig. 3e ), arguing against a simple autocrine effect of G-CSF. Taken together, these data further demonstrate that G-CSF-promoted tumour progression is mediated by MDSCs.
Pharmacological inhibition of mTOR may have confounding effects due to its roles in non-cancer cells. Diverse upstream signals may stimulate mTOR activity, some of which are more cancerspecific, such as activation of FGFR and loss of PTEN ( Fig. 2a ). Indeed, the induction of FGFR signalling in WNT1-iFGFR bigenic tumours led to a sevenfold increase of serum G-CSF ( Fig. 4a ). 4T1 cells are known to possess autocrine FGFR signalling 32 . Reanalysis of a published data set revealed that treatment of 4T1 cells by TKI258, a potent FGFR inhibitor, reduces Csf3 expression, the gene encoding G-CSF. Other MDSC-inducing cytokines did not exhibit the same trend ( Fig. 4b ). Furthermore, inhibition of the upstream FGFR signalling by BGJ398 also reduced G-CSF both in vitro ( Fig. 4c ) and in vivo ( Fig. 4d ). Accordingly, this inhibition also led to a significant reduction of MDSCs ( Fig. 4e ). Simultaneous inhibition of both EGFR and FGFR significantly reduced G-CSF expression in the P53N-C model ( Fig. 4f ), although targeting FGFR alone was ineffective, suggesting a redundant role of these receptor tyrosine kinases. Thus, G-CSF is a mediator of mTOR-driven MDSC accumulation. Targeting upstream activators of the mTOR pathway such as FGFR, therefore, may represent viable therapeutic strategies to mitigate MDSCmediated tumour progression, in addition to their direct effects on cancer cells.
Genomic analyses support the role of G-CSF and MDSCs in mTOR-driven immunosuppression and tumour progression
We examined the Cancer Genome Atlas (TCGA) 33 data sets comprised of genomic, transcriptomic and proteomic data of human breast cancers. To assess the G-CSF/MDSC status, we obtained a gene expression signature derived from the haematopoietic cells of human patients subjected to G-CSF treatment 34 . This signature (designated as G-CSF-sig) encompasses genes overexpressed by G-CSF-induced human haematopoietic cells. In TCGA data sets, the G-CSF-sig positively correlates with mTOR pathway activity as indicated by the RPPA data, and inversely correlates with T-cell antigen receptor (TCR) pathway genes ( Fig. 5a ). As one of the upstream activation signals, the genomic amplification and expression of FGFR positively correlated with the G-CSF-sig (Fig. 5a ). The correlation among FGFR, the G-CSF-sig, and the TCR genes was also confirmed in other clinical data sets ( Supplementary Fig. 4a-d) 35 , but not in a panel of breast cancer cell lines in vitro ( Supplementary Fig. 4e ), suggesting that this association is not due to intrinsic overlap between the gene sets, rather it seems to be dictated by non-tumour cells.
To further evaluate the mTOR pathway, we used two gene expression signatures denoting the responses of cancer cells to mTOR inhibitors, rapamycin 36 and pp242 (ref. 37 ). The G-CSF-sig inversely correlates with these signatures in gene set enrichment analysis ( Fig. 5b ), suggesting a positive association with mTOR activity. The G-CSF-sig is expressed at a higher level in both the Basal and Luminal B (LumB) breast cancer subtypes (Fig. 5c ), and correlates with the risk of distant metastasis (Fig. 5d ). The G-CSF-sig is associated with poor prognosis in multivariate prognosis analysis in two different data sets with long-term follow-up 35, 38 ( Supplementary Fig. 4f ).
Tumour-induced MDSC accumulation seems independent of the adaptive immune system as it was also observed in immunedeficient mice ( Supplementary Fig. 4g ). Therefore, it was possible to test human xenografts for their ability to induce MDSCs. A strong connection between mTOR activity and G-CSF expression was observed in a panel of patient-derived xenografts (PDXs) 39, 40 (Fig. 5e ). Specifically, we assayed pS6K(T389) as an indicator of mTOR activity by western blotting, and G-CSF expression by quantitative real-time PCR ( Supplementary Fig. 4h ). PDXs expressing a higher level of pS6K(T389) and G-CSF also induced more MDSCs in vivo ( Fig. 5f ). Moreover, treatment with mTOR inhibitors, rapamycin or Torin 1, reduced G-CSF in two of the PDX lines cultured in three-dimensional (3D) suspension medium ( Fig. 5g ).
Collectively, these data suggest that human tumours with an activated mTOR pathway are more likely to have an increased infiltration of MDSCs, a decreased infiltration of T cells and a worse prognosis.
TICs exhibit enhanced G-CSF production
In addition to inter-tumoral heterogeneity, we also observed an intratumoral heterogeneity of G-CSF production. Intracellular staining of G-CSF, pS6K(T389), pS6(S235-S236) and pSTAT3(S727) followed by fluorescence-activated cell sorting (FACS; Supplementary Fig. 5a ,b) revealed a correlation between G-CSF and mTOR activity at the single-cell level (Fig. 6a ). Among the top 5% of G-CSF high cells (>2 × mean) in 4T1 and P53N-C models, approximately 60-80% are CD24 high CD29 high , a widely used definition of TICs, as opposed to 30% in the entire population ( Fig. 6b and Supplementary Fig. 5c,d ). We then examined a different set of TIC markers, EpCAM and CD49f. Among P53N-C cells, the top 5% G-CSF high cells fell into two distinguishable populations, both expressing to different degrees EpCAM and CD49f. Together they account for over 80% of G-CSF high cells ( Fig. 6c ). Sca-1 and c-Kit have also been used as TIC markers in the 4T1 model 41 , and Sca-1 high c-Kit high cells were also enriched in the G-CSF high subpopulation of both 4T1 and P53N-C tumours ( Fig. 6d ). Taken together, these data support the conclusion that G-CSF high cells enrich for TICs.
The converse hypothesis that TICs overexpress G-CSF is supported by the elevated G-CSF level in CD24 high CD29 high cells and Sca-1 + c-Kit + subpopulations as indicated by FACS ( Supplementary  Fig. 5e ,f), or by enzyme-linked immunosorbent assay (ELISA; Fig. 6e ). Two independent experiments were performed with similar results. One representative experiment is shown. (b) Gene expression alteration of several cytokines related to MDSC expansion in 4T1 cells on treatment with TKI258 (n = 3 biological replicates, raw data available from GSE19222). (c) 4T1 cell viability (measured by WST-1 assay) and G-CSF quantity (by ELISA) are plotted as a function of concentration of BGJ398. All results are presented as percentage of control (untreated). For each data point, cells were cultured in three wells. The experiment was performed twice with consistent results.
One representative experiment is shown. (d) Quantification of serum G-CSF by ELISA in 4T1-tumour-bearing mice and tumour-free mice at the indicated time points and treatment. (e) Quantification of MDSCs in the blood of 4T1tumour-bearing mice at the indicated time points with or without BGJ398 treatment. For d,e, three independent experiments were performed with similar results. A representative experiment with n = 4 animals per group is shown. (f) Relative G-CSF concentration as measured by ELISA in the supernatant of P53N-C cells treated with the indicated drugs for 6 h. For each data point, cells were cultured in three wells. The experiments were repeated twice with consistent results. Error bars indicate s.e.m., and P values are calculated by two-tailed Student's t-tests. Statistics source data for a,d,e, are provided in Supplementary Table 4 .
A similar conclusion was also reached using EpCAM and CD49 as markers ( Supplementary Fig. 5g ,h).
To investigate whether TICs have enhanced ability to induce MDSC differentiation as compared with non-TICs, we treated primary bone marrow cells of naive mice with tumour-cellconditioned medium. On a per-cell basis, tumour cells grown under a TIC-enriching condition (mammospheres in suspension medium 42 ) secreted more G-CSF than under the condition favouring differentiation (2D cultures). Accordingly, tumour-conditioned medium obtained under the TIC-enriching condition induced increased MDSCs (CD11b + Ly6G + Ly6C variable ). This increase was reversed by G-CSF-neutralizing antibodies ( Supplementary Fig. 5i ).
To test the above conclusions in human cancer, we analysed a SAGE (serial analysis of gene expression) data set of purified CD44 + and CD24 + cancer cells 43 . CSF3 transcripts were exclusively found in CD44 + cells but not CD24 + cells, suggesting that cancer cells with TIC-like phenotype overexpress G-CSF (Fig. 6f ). CD44 + cells also express a significantly higher level of FGFR1 transcripts (Fig. 6g ). To examine whether CD44 + cells may possess increased activity of the FGFR and mTOR pathway, we intersected the CD44 +associated genes 43 with gene expression signatures that reflect mTOR inhibition 37 by rapamycin or FGFR inhibition by TKI258 (ref. 32) , and discovered statistically significant overlaps ( Fig. 6h ). Finally, we treated human primary bone marrow cells with conditioned medium from PDX cells. The TIC-enriched conditioned medium induced more differentiation of CD11b + CD33 + CD15 + CD16 − cells ( Supplementary Fig. 5j ), which are known to be immature granulocytic cells 9, 44 . Taken together, these results provide evidence for the clinical relevance of the connection between TICs, G-CSF and MDSCs.
Genomic amplification
Overexpression FGFR1, 2 and 3: Supplementary Table 4 . 
MDSCs enhance TIC features through Notch signalling
We asked how MDSCs contribute to tumour initiation. MDSCs have been shown to promote angiogenesis 24, 45 . The perturbation of the mTOR-G-CSF axis did not seem to affect tumour angiogenesis, as suggested by immunofluorescence staining of CD31 ( Supplementary  Fig. 6 ). Monocytes and macrophages have been shown to enhance TIC features 46 . We asked whether granulocytic MDSCs have similar functions. The presence of MDSCs increased the number of mammospheres formed by 4T1 cells ( Supplementary Fig. 7a ). Moreover, MDSCs also disproportionally increased the number of cancer cells expressing murine mammary TIC markers including CD24, CD29, CD49f, Sca-1 and c-Kit ( Supplementary Fig. 7b ). Coculturing with MDSCs stimulated several stemness-related genes in cancer cells, including Nanog, LGR5 and MSI-1 (ref. 47) ( Fig. 7a ). Cancer cells extracted from 4T1 tumours with G-CSF knockdown exhibited reduced frequencies of CD24 high CD29 high cells and EpCAM high CD49f + cells (Fig. 7b) , and a decreased ability to form mammospheres ( Supplementary Fig. 7c ). These alterations could be rescued by adoptive MDSC transfer ( Fig. 7b ), suggesting that MDSCs contribute to the expansion of TICs in vivo.
Taken together, these data indicate that MDSCs enhance the tumour initiation. Direct cell-cell interaction seemed to be critical for this function, as MDSCs separated in the Boyden chambers were unable to enhance the stemness-related genes (Fig. 7a ). This points to pathways that require cell juxtaposition and dictate stem or progenitor cell properties. The Notch pathway meets these criteria 48 . Indeed, MDSC co-culturing significantly increased expression of multiple canonical Notch target genes in a contact-dependent fashion (Fig. 7c ). To determine whether this increase is restricted to cancer cells, we transduced a Notch reporter 49 into cancer cells, and observed that the reporter activity was enhanced by MDSCs. This enhancement was abolished by coexpression of a dominant-negative (DN) mutant of Rbpj 50 or MAML 51 in cancer cells (Fig. 7d) . Consistently, the MDSC-mediated increase of CD49 + EpCAM high cells was reduced by DN-MAML or DN-Rbpj (Fig. 7e ). Normal neutrophils were unable to induce the same effects (Fig. 7e ). In human models, co-culturing of MDSCs and MC1 or HCI11 cells (isolated from the respective PDX models) significantly increased the proportion of CD44 + CD24 − cells (Fig. 7f ). This increase was almost completely abolished by a Notch inhibitor, semagacestat ( Fig. 7f) . Finally, the G-CSF-sig correlates with Notch target genes in the TCGA data set (Fig. 7g ). Taken together, these results strongly support that MDSCs enrich TICs through Notch signalling in cancer cells.
To test the impact of mTOR-MDSC cascade on tumour initiation in vivo (Fig. 8a) , we transiently treated P53N-C-tumour-bearing mice with rapamycin. A subset of the rapamycin-treated mice also received transplantation of exogenous MDSCs to selectively rescue the MDSC-mediated effects downstream of the mTOR pathway. The tumours were then subjected to tumour initiation assays without further rapamycin or MDSC treatment. As expected, compared with control tumours, rapamycin-treated tumours exhibited a significant decrease of CD29 + EpCAM high CD49f + cells (Fig. 8b) . Provision of exogenous MDSCs reversed this decrease (Fig. 8b) . When transplanted into untreated mice at high cell numbers (5,000 and 1,000 cells per mouse), the rapamycintreated group exhibited slower tumour progression ( Fig. 8c and Supplementary Fig. 7d ). At low cell numbers (200 cells and 40 cells per mouse) tumour initiation is significantly delayed in this group ( Fig. 8d and Supplementary Fig. 7e ). There was also a statistically significant decrease of TIC frequency compared with the other groups (P = 0.016 by extreme limiting dilution analysis 52 ). The effects of rapamycin on tumour size, latency and TIC frequency were all partially reversed by concomitant transfer of MDSCs (Fig. 8c,d and Supplementary Fig. 7d,e ). These data show that the transient inhibition of mTOR signalling reduced TIC frequency, and, more importantly, this reduction is partially mediated by MDSCs.
DISCUSSION
Our results indicate that mammary tumours relying on different oncogenic pathways may also differ in their ability to alter the immune system. Recent genomic studies have suggested enormous heterogeneity of tumour-infiltrating immune cells [53] [54] [55] . However, why and how different tumours evolve to enrich distinct immune cells remains poorly understood. Here, our data demonstrate how a tumour cell-intrinsic oncogenic pathway, the mTOR pathway, determines a tumour's capacity to accumulate granulocytic MDSCs, providing one partial answer to these questions.
Our data demonstrate that G-CSF is a downstream target gene of the mTOR pathway, and mediates MDSC accumulation. The roles of MDSCs and G-CSF in tumour progression and therapeutic responses have been elucidated 12, 13, 16, 18, 31 . However, the role of mTOR-G-CSF cascade has not been reported, and these results extend the oncogenic functions of the mTOR pathway from a cancer cell-intrinsic to a systemic level. Our data suggest a therapeutic strategy to combine current immunotherapies with mTOR inhibitors, which has already been applied to endocrinetherapy-resistant ER + tumours in the clinic 56 . A recent study used a PI(3)K inhibitor and demonstrated synergistic effects with immune checkpoint blockade 57 , supporting that inhibition of the PI(3)K-mTOR pathway may help overcome immunosuppression and enhance immunotherapies. A potential caveat of this strategy is that the PI(3)K-mTOR pathway also plays an important role in T cells 58 . As a result, PI(3)K and mTOR inhibitors themselves are expected to be immunosuppressive. Here, our data provided mechanistic insights into potential upstream targets including FGFR and G-CSF. Drugs blocking FGFR or G-CSF may inhibit MDSC accumulation without potentially detrimental effects on the adaptive immune system.
MDSCs enhance TIC features. This is consistent with the previously reported role of MDSCs in ovarian cancer 59 . The mechanism here, however, seems to be distinct-through the Notch pathway in tumour cells. In addition, our data also indicate that TICs enrich the ability to produce G-CSF, and hence contribute more significantly to MDSC accumulation. Taken together, we identified a feedforward loop between TICs and MDSCs, suggesting that the tumorigenic potential may evolve hand in hand with tumour-induced immunosuppression.
Among the variety of tumour models we examined, only a subset resulted in granulocytic MDSC accumulation. Thus, these cells are not universally required, and there may be different immune cells playing distinct roles in other tumour contexts. For instance, another major type of MDSC, monocytic MDSCs, also possess potent immunosuppressive activities 37 . Further studies will be necessary to determine whether monocytic MDSCs are involved in different subsets of breast cancers, and are regulated by different oncogenic pathways. Supplementary Table 4 . Supplementary Table 4 .
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper METHODS Animal studies and tumour models. All animal experiments were carried out in accordance with a protocol approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. Female animals of 5-6 weeks are used as the recipients of tumour tissue or cell line transplantation. BALB/C and SCID/Beige were used as recipients of syngeneic tumours (P53-null series and 4T1-4TO7-67NR cell line series) or PDXs, respectively. MMTV-WNT1, MMTV-WNT1-iFGFR and P53-PTEN DKO mice are in the FVB background.
The mouse breast cancer models were as follows: P53N-A (formerly assigned T11), P53N-B (formerly assigned 2225L) and P53N-C (formerly assigned 2208L) from our P53-null mouse mammary tumour bank described in ref. 28 are on the BALB/C background and were used in syngeneic BALB/C mice unless stated otherwise. Models on the FVB background and maintained in FVB strain of mice: MMTV-Wnt1 (termed Wnt1 for brevity) and MMTV-Wnt1 tumours transduced with inducible FGFR (termed Wnt1-iFGFR) have been described elsewhere 27 . The P53-PTEN DKO was generated by conditional deletion of these tumour suppressors using a MMTV-driven Cre through nipple-injection of adenoviral Cre into transgenic mice carrying respective Flox alleles of P53 and PTEN.
Breast cancer PDXs were maintained by injecting 1-2 mm size tumour pieces into fat pad-cleared mammary glands of SCID Beige mice. The development of PDX lines was conducted under the Institutional Review Board-approved protocols, and was documented in previous studies 39, 40 . The current study used already-established PDXs that had been de-identified, and therefore, has been granted protocol exemption by the Institutional Review Board of Baylor College of Medicine for not involving human subjects. PDXs used in this study: HCI11 (ER + , FGFR + ), HCI3 (ER + ), BCM3143 (Her2 + ) and triple-negative subtype MC1, BCM2147, BCM4272 and BCM4195, which were obtained from two independent sources 39, 40 .
Cell lines. None of the cell lines used in this study is listed in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. 4T1, 4TO7 and 67NR cell lines were purchased from Karmanos Cancer Institute. No cell line authentication was performed. Cell lines were subjected to bi-monthly tests for mycoplasma contamination.
Lentivirus transduction of tumour cells. The expression vector for a firefly luciferase-GFP fusion protein (FLUC-PWIPZ) was packaged into lentivirus in 293T
cells with pMD2 and pSpAX2 packaging system. Lentiviral stocks were filtered and concentrated by ultracentrifugation. To label P53N-C tumour cells, tumours were digested into single-cell suspensions by collagenase 3 treatment, and incubated with FLUC-PWIPZ lentivirus and Polybrene for 24 h under mammosphere assay conditions to preserve tumour characteristics. At 48 h culture period, successfully labelled cells were isolated by FACS sorting of GFP-positive cells and injected into mammary glands of BALB/C mice for tumour development. Tumours that retained GFP and luciferase signal (about 40% of tumours) were collected and comprised the tumour stock used in experiments.
4T1 cells were transduced with G-CSF-specific shRNA, Raptor-specific shRNA or a scramble-control nonspecific shRNA using the lentiviral GIPZ vector system (Thermo Scientific Open Biosystems) that allows puromycin selection to obtain a pure transduced cell population. Knockdown efficiencies were determined by genespecific real-time qPCR and by ELISA (R&D Systems) for G-CSF or by quantitative western blotting for Raptor (Odyssey System, rabbit anti-raptor, Cell Signaling Technology). P53N-A model-derived tumour cells were transfected using Xtreme Gene HP DNA Transfection Reagent (Version 08, Roche) with expression plasmid for a constitutively active mTOR mutant, pcDNA3-AU1-mTOR-S2215Y, which was a gift from F. Tamanoi, Tarbiat Modares University, Iran (Addgene plasmid no. 26037).
In vivo treatments. 1-2-mm-size tumour pieces were implanted orthotopically, in the fourth mammary gland on the left side of the animal. When tumour size reached an average of 80 mm 3 , treatments were initiated as indicated in figure legends. In all experiments, the initial implantation was conducted on animals at the age of 5-6 weeks.
BGJ398 was dissolved at 10 mg ml −1 in dimethylsulfoxide (DMSO), and mixed with PEG300/5% glucose (3:1) to administer by oral gavage (15 mg kg −1 , daily, 5 d per week).
Rapamycin was administered by intraperitoneal (i.p.) injection (100 µg in 200 µl of 10% PEG400, 10% TWEEN80 and 4% ethanol, dosage was at 5 mg kg −1 , three times per week).
Anti-Ly6G treatments comprised of two i.p. injections per week of 100 µg anti-Ly6G (BioXCell) in PBS. Anti-G-CSF (R&D Systems) was i.p.-injected daily, five times per week, at 10 µg injection dose. Control animals received an equal amount of isotype-control antibody (BioXCell).
Recombinant human G-CSF (Novoprotein, specific activity: 6 × 10 7 IU mg −1 ) was injected subcutaneously in the flank at 1.5 µg per injection in 150 µl PBS every 2 days for the duration indicated in the figures.
Gr1 + cells of tumour-bearing mice (MDSCs), or for controls, from tumour-free mice, were enriched using a magnetic cell separation kit (Biotinylated anti-mouse Gr1, BD Pharmingen, Biotin Selection Kit, Stem Cell Technologies) yielding >95% purity. For in vivo transfer, cells were washed in PBS and immediately injected through the retro-orbital route. Two consecutive injections of 4 × 10 6 cells spaced 5 d were applied.
Tumour and tissue analysis. Tumour length (L) and width (W ) were measured with a calliper. Tumour volumes were calculated using the formula L * W 2 * π/6. MDSCs in tumour sections were identified by immunohistochemistry with anti-S100A8 (clone 335806, R&D Systems). Immunofluorescence staining of 5 µm tumour sections was carried out as previously described 60 . To assess tumour vascularity, tumour sections were stained with CD31 antibody, followed by DAPI staining of nuclei. Images of stained sections were analysed for number of S100A8 + cells, number of DAPI + nuclei, and area covered by CD31 with the help of ImageJ and Photoshop. The images shown in Fig. 1a,f and Supplementary Fig. 6 are representative of at least five randomly picked fields from multiple tumours.
Lung metastasis was quantified by bioluminescence imaging (luciferaselabelled tumour cells) or enumeration of visible lesions: on euthanization, animals were perfused with PBS, and lungs were excised and immediately subjected to bioluminescence measurement with IVIS Lumina II equipment. Then lungs were fixed in 4% PFA and visible lesions were counted with the aid of a magnifying stereoscope. Lung metastasis nodules were counted by two people who were blinded with regard to a sample's experimental-group origin. Severity of metastasis was scored on the basis of these metastasis nodule counts. Paraffin-embedded lung samples were also submitted to haematoxylin and eosin (H&E) staining to reveal the size of lung metastases. For quantification, 10 stacked H&E-stained sections per lung, spaced 200 µm to cover a representative portion of the whole lung, were evaluated. Sections were scanned and total lung area and metastasis-covered area were measured using Photoshop. Figures 1k and 3h,j show the average level of lung metastasis burdens in their corresponding group (group sizes indicated in the corresponding figure legends).
Blood was drawn and collected in EDTA-coated tubes. To separate plasma from blood cells, a 15 min centrifugation at 1,500g , 4 • C, was performed. Plasma was stored at −80 • C before analysis by Bioplex (23-cytokines-kit, Biorad) or ELISA (mouse G-CSF DuoSet, R&D Systems). Blood cells were subjected to red blood cell lysis, followed by FACS staining or other analyses.
Flow cytometry of blood and tumour samples. To characterize and quantify
MDSCs by FACS, cells were incubated with FcR blocker (eBioscience), and then stained with Ly6C-PE-CF594 (BD Biosciences), Ly6G-PerCPCy5.5 (BD Bioscience), CD11b-APC (eBioscience) and/or anti-GR1 (RB6, BD Biosciences). MDSCs were identified as GR1 + CD11b + cells, granulocytic MDSCs as Ly6G high Ly6C low or -CD11b + , monocytic MDSCs as Ly6C high Ly6G low CD11b + . To determine absolute cell numbers counting beads (BD Biosciences) were added before FACS acquisition. T cells were analysed with an antibody combination of CD3-PerCPCy5.5, CD4-APC, CD8-FITC (all eBioscience) and PD1-PE-CF594 (BD Biosciences). Also see Supplementary Table 2 for antibody use information.
Tumour-infiltrating MDSCs and T cells were quantified by enzymatic digestion of the dissected tumours (mouse tumour cell dissociation kit, Miltenyi Biotec), followed by FACS staining with the above antibody combinations. Staining for the common leukocyte marker CD45 was also included to facilitate the distinction of leukocytes from tumour cells and other stromal cells.
Reverse-phase protein array. RPPA assays were carried out as described previously 61 with minor modifications. Protein lysates were prepared from tissue samples with Tissue Protein Extraction Reagent (TPER; Pierce) supplemented with 450 mM NaCl and a cocktail of protease and phosphatase inhibitors (Roche Life Science). Protein lysates at 0.5 mg ml −1 of total protein were denatured in SDS sample buffer (Life Technologies) containing 2.5% 2-mercaptoethanol at 100 • C for 8 min. The Aushon 2470 Arrayer (Aushon BioSystems) with a 40-pin (185 µm) configuration was used to spot lysates onto nitrocellulose-coated slides (Grace Bio-labs) using an array format of 960 (experimental and controls) lysates per slide with each sample spotted as technical triplicates (2,880 spots per slide). Slides were prepared for antibody labelling by blocking for 1 h with I-Block reagent (Applied Biosystems) followed by 15 min incubation with Re-Blot reagent (Dako). Antibody labelling was performed at room temperature with an automated slide stainer Autolink 48 (Dako) using specific primary antibodies and appropriate biotinylated secondary antibody (Vector). An amplified fluorescent detection signal was achieved with Vectastain-ABC Streptavidin-Biotin Complex (Vector, PK-6100) followed by TSA-plus Biotin Amp Reagent diluted at 1:250 (Perkin Elmer, NEL749B001KT) and a 1:50 dilution DOI: 10.1038/ncb3355 of LI-COR IRDye 680 Streptavidin (Odyssey). The total protein content of each spotted lysate was assessed by fluorescent staining with Sypro Ruby Protein Blot Stain for selected subset of slides (Molecular Probes). Fluorescent-labelled slides were scanned on a GenePix AL4200 scanner, and the images were analysed with GenePix Pro 7.0 (Molecular Devices). For normalization, raw image intensity of each spot is subtracted by that of negative control and then divided by total protein values. Tumours with different genetic backgrounds are analysed separately.
Western blotting. Tumour lysates described in the RPPA section above were also subjected to gel electrophoresis using 25 µg protein per lane of pre-cast 4-12% gradient minigels (Novex, Life Technologies), followed by transfer onto nitrocellulose membrane (Novex, Life Technologies), blocking with 5% dry milk in TBST for 1 h, shaking with supplier-recommended concentration of primary antibodies (all from Cell Signaling Technology) at room temperature for 4 h or at 4 • C overnight, and developing with secondary antibodies that were labelled for detection with the Odyssey system. Labelled molecular weight marker was also loaded on the gels. Protein bands were quantified using Odyssey features with scan times set to exclude overexposure. For representative images shown in Fig. 2b and Supplementary Fig. 2 , at least three independent experiments were performed with similar images obtained.
In vitro T-cell activation assay. T cells of naive BALB/C mice were enriched from spleen by negative selection on magnetic beads (removal of TER119 + , B220 + and CD11b + cells) and labelled with CFSE (1 µM, Molecular Probes). T cells were cultured alone or admixed with MDSCs (at 1:0.33, 1:1 and 1:3 ratios) in 96-well plates. T-cell activation was with anti-CD3 (coating of wells at 5 µg ml −1 overnight, 4 • C) and IL-2 (huIL-2, 5 ng ml −1 ). At 5 days of culture, cells were collected and CFSE dilution was determined by FACS. Samples were also stained for Ly6G, to be able to exclude non-T-cells (MDSCs) from the analysis.
Cell culture supernatants were also collected and analysed by Bioplex assay of IFN-γ.
In vitro drug treatment. 4T1 cells were purchased from the Barbara Ann Karmanos Cancer Center. 2208L cells were derived from P53N-C tumours by continuous culture for more than one year. They were shown to express high E-cadherin levels suggesting the maintenance of luminal subtype of breast cancer characteristics and were apparently free of stromal components (only p53N genotype detected) at the time of use. Routine mycoplasma inspection was performed bi-monthly to ensure negativity of infection. No STR profiling or other authentication procedures have recently been performed. For drug treatment experiments, cells were seeded at 100,000 cells per well in 12-well format, or 10,000 cells per well of 96-well format the day before the experiment. Drug treatments were done after one wash in FBSfree DMEM (high glucose) medium for 8 h or 24 h as indicated in the figures. BGJ398 (Novartis), Torin 1 and lapatinib stocks were prepared in DMSO at ×1,000 of final concentration. Rapamycin was dissolved at ×1,000 of final concentration in ethanol. Control cells received corresponding amounts of vehicle alone. Cell supernatants were collected and, after a brief spin, analysed on G-CSF-ELISA plates (mouse G-CSF DuoSet, R&D Systems). In cell survival assays, WST-1 reagent (Roche) was added at end of the drug treatment period following the supplier's instructions and attenuance D 450 nm was measured.
Tumour initiation assay. P53N-C tumours were extracted and dissociated into single-cell suspension. FACS was employed to remove lineage-positive cells and dead cells. The remaining cancer cells were serially diluted into 50,000, 10,000, 2,000 and 400 cells ml −1 . A 100 µl cell suspension was transplanted into cleared mammary fat pads of recipient mice.
Mammosphere assay. Tumour cells (20,000 cells per well) were cultured in a lowadhesion 24-well plate in DMEM/F12 medium with murine bFGF (20 ng ml −1 , Life Technologies), murine EGF (20 ng ml −1 , Life Technologies) and B27 supplement (GIBCO). For co-culture, 80,000 Gr1 + MDSCs were added. As indicated, in some instances MDSCs and tumour cells were co-cultured in Boyden chambers, putting MDSCs on insets with 0.4-µm-pore-size membranes. Co-culture periods were 5 h for RNA expression study, 24 h for FACS of cancer stem cell surface markers, and 6-12 d to determine mammosphere-forming units. As indicated in the figures, specific control groups received Gr1 + cells of tumour-free mice (NNs, normal neutrophils) instead of Gr1 + MDSCs. These control cells were isolated from bone marrow with the same magnetic sorting procedure used for MDSCs (biotinylated anti-mouse Gr1, BD Pharmingen, Biotin Selection Kit, Stem Cell Technologies). Mammospheres were enumerated by manual counting of low-magnification images of the cultures (GelCount). The images in Supplementary Fig. 7a are representative of over 20 images obtained from different experiments. For flow cytometry, mammospheres were dissociated by trypsin-EDTA digestion. Total tumour cell counts were obtained by FACS of the GFP-tagged tumour cells.
FACS of G-CSF, phospho-S6K, breast cancer stem cell markers.
Single-cell suspensions of tumour cells were incubated on ice with FcR blocker (eBioscience) in staining buffer (1% FBS in PBS), followed by cell surface marker staining with the following antibodies: CD24-PE, Epcam-APC, ScaI-PE, CD29-PECy7, CD49f-eFLUOR450, c-Kit-APC and CD45-eFLUOR450 as indicated in the figures. When intracellular staining was carried out, cells were fixed and permeabilized using reagents of eBioscience's FOXP3 staining kit. Intracellular staining was performed in the presence of 2% normal mouse serum, 2% normal goat serum and 2% FBS to reduce nonspecific binding. Antibodies used were G-CSF-APC (eBioscience) and rabbit anti-pS6K(T389, Cell Signaling), rabbit anti-pS6 (S235/236, Cell Signaling) or rabbit anti-pStat3(S727, Cell Signaling) followed by goat anti-rabbit-eFluor488.
For analyses of CSCs in tumour tissues, we first performed tumour dissociation using gentle MACS dissociators and tumour dissociation kit manufactured by Miltenyi Biotec. The cell suspension was then subjected to the staining described above. Owing to technical variations, tumours collected together and analysed at the same time were considered as an experimental set, and the systematic differences between different sets were removed by normalization (setting the mean frequencies of 'No treatment' samples as one within each set).
Co-culture of human bone marrow cells with human breast cancer PDX cells.
Cell suspensions of PDX tumour cells were prepared with Miltenyi Biotec tumour dissociation kit as described above. To obtain tumour-cell-conditioned media, 1 × 10 6 tumour cells ml −1 were cultured for 3 days under mammosphere conditions (3D condition, low-adhesion plate, mammosphere medium described above) or on regular culture plates (2D condition, DMEM-high glucose with 10%FBS). Cell supernatant was collected, cleared by centrifugation and stored at −20 • until use.
Unprocessed human bone marrow was obtained from healthy volunteers (Poietics, consent agreement with vendor, Lonza). Red blood cells were removed by lysis.
In treatments with tumour-conditioned media, 1 × 10 6 bone marrow cells per well of a 24-well plate were cultured in IMDM medium (IMDM, 10% heat-inactivated FBS, 0.01 M HEPES, 55 µM 2-mercaptoethanol, 1% antibiotic/antimicotic). To keep culture conditions consistent between groups, controls received 7.5% of 3D plus 7.5% of 2D non-conditioned tumour cell culture medium and experimental groups received 7.5% of 3D tumour-cell-conditioned medium plus 7.5% of non-conditioned 2D medium, or 7.5% of 2D tumour-cell-conditioned medium plus 7.5% of non-conditioned 3D medium, respectively. Similar experiments with mouse bone marrow cells and mouse breast cancer cell line 4T1 were carried out under the same conditions. G-CSF-neutralizing antibody was added as indicated in the figures, at 6 µg ml −1 (approximately five times ED 50 based on information provided by the supplier). Recombinant human G-CSF (Novoprotein) was used at 40 ng ml −1 (specific activity: 6 × 10 7 IU mg −1 ).
After 3-day culture, cells were analysed by FACS. Cells with the phenotype of CD11b + CD33 + CD15 + CD16 − HLA-DR -/low (human) or CD11b + Ly6G + (mouse) and granulocytic characteristics in the FSC-SSC profile were enumerated and assigned as granulocytic myeloid-derived suppressor cells.
Human bone marrow cells were also directly co-cultured with PDX tumour cells at a 4:1 ratio under mammosphere conditions. At the end of the 8-day culture period, the CD24 and CD44 profile of tumour cells was determined by FACS. Tumour cells and bone marrow cells were discriminated on the basis of FSC and SSC properties and CD11b.
PDX cell co-culture with MDSCs. PDX MC1 cell suspensions were prepared as described above, cleared of mouse stromal cells using mouse cell removal kit (Miltenyi Biotec) and mixed with purified MDSCs (Gr1 + ) from blood of MC1tumour-bearing mouse and cultured under mammosphere conditions. The human cancer stem cell phenotype CD24 − CD44 + was determined by flow cytometry with anti-human CD24-PECy7 (eBioscience) and anti-human CD44-PE (Biolegend) and included a mouse MDSC marker staining to facilitate the exclusion of this population by gating during data analysis.
Notch pathway studies. The γ-secretase inhibitor semagacestat (Selleck Biochem) was dissolved in DMSO as 10 mM stock and used at 10 µM final concentration. Controls received the same amount of DMSO. For assays of Notch pathway activation, the Notch reporter plasmid pCBFRE-luc, a gift from N. Gaiano, Johns Hopkins University School of Medicine, USA (Addgene plasmid no. 26897), was used. The Notch reporter was co-transfected with a constitutive expression (EF1α promoter-driven) Renilla luciferase plasmid. Firefly luciferase (Notch reporter) and Renilla luciferase bioluminescence activity were measured by an in vivo imaging system (IVIS) and determined consecutively by adding respective substrates (D-luciferin, Gold Biotechnology and RediJect Coelenterazine h, PerkinElmer, respectively) and included background measurements before and between reporter analyses. Notch reporter signal was normalized to the signal from constitutive plasmid. Dominant-negative forms of RBPJ (DN-RBPJ) and MAML (DN-MAML) were applied to inhibit the intracellular Notch pathway. This was done either by cotransfection in the Notch reporter assays or using lentiviral transduction followed by GFP-based flow cytometric sorting to remove non-transduced cell population.
Bioinformatics analysis. The TCGA data set was obtained from the TCGA Data Portal in December 2012. Data for different platforms were matched on the basis of patient identifiers. Patients with incomplete records of DNA-copy number, mRNA expression, or RPPA data were excluded. The EMC-MSK data set was derived as described in the previous study 62 . The METABRIC data set 38 was described elsewhere and obtained from Cancer Research UK, Cambridge Research Institute. The FGFR signature was derived from a previous study by comparing MMTV-WNT-iFGFR tumours with MMTV-WNT tumours 27 . The genes that are significantly altered by inducible activation of FGFR1 were determined using a cutoff of FC (fold change) >2 and P < 0.05 (by two-sided Student's t-tests). The signature was then applied to the gene expression profiles of p53-null tumours. Specifically, a single-value score was computed using the formula:
G↑-G↓, where G↑ represents the expression values of upregulated genes and G↓ represents the expression values of downregulated genes. The G-CSF signature was derived on the basis of a previous study using the same approach as for FGFR signature. In Fig. 3b , we used GSE19222 to analyse the effect of an FGFR inhibitor, TKI258, on the expression of multiple cytokines. In Supplementary Fig. 4e , we used GSE12777 to gauge the correlation between G-CSF-sig and TCR genes in cell lines.
Gene Set Enrichment Analysis (GSEA) software was downloaded from the website http://www.broadinstitute.org/gsea/index.jsp. Gene signatures reflecting the action of pp242, rapamycin and G-CSF were derived from previous studies 34 . A continuous score of G-CSF signature was computed using a similar approach as described in the previous paragraph for the FGFR signature. GSEA was applied to the TCGA data set using genes up-or downregulated by pp242 and rapamycin as gene sets 36, 37 , and G-CSF signature scores as the continuous phenotype indices. P values of the enrichment were computed using built-in algorithms of GSEA based on random simulation.
Kaplan-Meier curve generation and tests (Fig. 4d ), multivariate fitting of Cox proportional hazard model ( Supplementary Fig. 4F ), gene expression comparison across different molecular subtypes (Fig. 4c) , and other data mining procedures and statistical assessments were performed using R Statistical Software on the basis of log-rank tests.
RT-qPCR.
RNA was collected and processed in TRIZOL, reverse transcribed to cDNA with Applied Biosystems' High Capacity Reverse Transcription Kit, and analysed by real-time qPCR on an ABI7500 Fast Real-time PCR machine using SsoFast EvaGreen QPCR reagent (Biorad). Results were normalized to beta-actin and/or GFP (tumour cell label) and relative values were calculated as 2 [-(CTgene -CT reference)] . Gene-specific primers used are listed in Supplementary Table 3 .
Statistics and reproducibility.
All results are presented in the form of mean ± s.e.m. unless otherwise specified. Sample sizes for in vivo experiments are noted in the corresponding figures or figure legends. Individual animals and independently prepared or treated primary tissue samples (for example, PDXs and primary human bone marrows) are considered as biological replicates. Different wells in one experiment are considered as technical replicates. In each experiment the size is determined on the basis of our prior knowledge of the variability of experimental output. Specifically, in animal experiments, a sample size of 4-8 mice per group allows us to detect a 50% difference in tumour size with power of 60-85% and α = 0.05. Animals that suffered non-cancer-related disease conditions (for example, pathogen infection) were diagnosed by the Center of Comparative Medicine at Baylor College of Medicine on the basis of routine inspection, and excluded from experiments as per the recommendation of veterinarians based on pre-established protocols. Otherwise, animals were included into analyses. For the experiments shown in Figs 2g,h, and 3g, a randomization process was performed by randomly assigning animals into two separate groups. After assignment, tumour sizes of the two resultant groups were compared to make sure there is no statistically significant difference (by two-sided Student's t-test). No randomization was performed in other experiments. The researchers were not blinded to allocation during experiments and outcome assessment except for experiment in Fig. 3j , in which the results were assessed by a researcher blinded to group allocation. For in vitro experiments including FACS analyses, in most cases two to three independent experiments were performed each with three to six technical replicates. Specific information is included in the corresponding figure legends. No specific tests were conducted to test the assumption of normal distribution. The difference between means of different experimental groups was analysed using two-tailed unpaired Student's t-test unless otherwise noted in respective legends. F-tests were performed to compare variation within different groups, and t-tests were performed with or without the assumption of equal variation accordingly. In a few experiments (see Fig. 7e ,f), we computed P values in the framework of two-way ANOVA to achieve more stable estimates of biological variations by collectively analysing multiple biological conditions or perturbations. Specifically, in Fig. 7e , we treated different genetic perturbations (control, DN-Rbpj, and DN-Maml) as one factor, and different co-culture conditions (control, +MDSCs, and +NNs) as the second factor. In Fig. 7f , we used different co-culture conditions (with or without MDSCs) as one factor, different PDX models (HCI11 and MC1, left panel) or different treatments (with or without Notch inhibitor, right panel) as the second factor. Two-way ANOVA tested the null hypotheses that there is no significant difference among different levels of the same factor and there is no interaction between the two factors. The analyses were performed using the built-in two-way ANOVA analysis tool in Excel. Detailed output including results of post hoc tests is provided in Supplementary Table 4 .
Accession numbers and data sets. Referenced accessions: previously published microarray data that were reanalysed here are available from GEO under accession codes GSE7400 34 , GSE19222 32 and GSE12777 63 . The EMC-MSK data set 62 is comprised of GSE2603, GSE5327, GSE2034 and GSE12276. The METABRIC data set 38 is deposited at the European Genome-Phenome Archive (http://www.ebi.ac. uk/ega), which is hosted by the European Bioinformatics Institute, under accession number EGAS00000000083.
Erratum: Oncogenic mTOR signalling recruits myeloidderived suppressor cells to promote tumour initiation Figure 1 Inter-tumoral heterogeneity of MDSC accumulation in mammary tumor models. a. Quantification of S100A8+ cells identified by immunofluorescence staining. Six fields were randomly picked from each tumor, and three tumors were included. b. Relative expression of the S100A8 gene in the bulk of tumor and in CD11b + Gr1 + cells purified from the tumor by FACS. n=2 and 5 tumors for the bulk tumor and purified Supplementary Fig. 3b-d are provided in Supplementary Table 4 . Supplementary Figure 5 . Correlation between high G-CSF expression and TIC features. a. 4T1 control cells and 4T1 cells expressing G-CSF shRNA were subjected to intracellular G-CSF FACS staining procedure. Overlay-graph demonstrates changes in GCSF levels. The experiment was performed twice with similar results. Results of a representative experiment are shown.b. Staining specificity control for pS6K antibody: PS6K levels were measured by intracellular FACS staining in 4T1 cells cultured in medium without serum (starved) or with 10% FBS. c. Cells with highest G-CSF expression (top 5.3%, expression >2 times mean of total population) were compared to whole 4T1 cell population in the expression of CD24/CD29. Representative plots of gating strategy and identification of CD24 high CD29 high cells. d. Same analysis as in c, for P53N-C model. In c and d: Representative of three FACS staining experiments with 2-3 stained samples per experiment. e. 4T1 cells were stained for GCSF, CD24 and CD29. Expression of GCSF in CD24 high CD29 high cells and in the total population was compared. f. Same analysis as in (e), for P53N-C cells. g-h. Correlation between GCSF and Epcam + CD49f + cells; analysis was done as described for CD24 high CD29 high cells in e. In h, EpCAM high CD49f med and EpCAM med CD49f high denote specific cell population
in P53N-C model as described in Fig. 6c . Supplementary Table 4 . 
Scramble Control
Supplementary Figure 6 The mTOR-G-CSF-MDSC axis does not affect tumor angiogenesis. Immunofluorescence staining of CD31 was performed to quantitate angiogenesis in 4T1 tumors with indicated treatments. The CD31+ area was assessed using ImageJ software and displayed in the right panel. n=8, 7, 6, and 5 fields randomly picked from 4 different tumors for the four groups, respectively. n.s.: no significance. Scale bar, 100μm. Supplementary Fig. 7b is provided in Supplementary Table 4 . 
